Overview

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Status:
Completed

Trial end date:
2017-12-12

Target enrollment:

Participant gender:

Summary

This is an 8 week study to assess the efficacy and safety profile of PF-06651600 in seropositive subjects with rheumatoid arthritis with an inadequate response to methotrexate (up to approximately 50% of subjects may also have had an inadequate response to 1 anti-TNF biologic).

Phase:

Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Methotrexate